Daniel A. Vorobiof, MD, the chief medical director of Belong.Life, discusses the impact of financial toxicity on patients with cancer.

Financial toxicity has become a growing concern for several patients with cancer, as well as their caregivers, says Vorobiof. As treatment costs continue to rise, Vorobiof says that financial toxicity is a challenge that can no longer be ignored. A cancer diagnosis is often accompanied by substantial financial burden, and although this is not a new issue, it must be addressed, Vorobiof says.

Real-world data from several clinical studies indicate that financial toxicity is a major factor that impacts outcomes and the quality of life of patients, spanning different tumor types and treatments received, Vorobiof concludes.

Videos

Dr. Vorobiof on the Impact of Financial Toxicity in the Field of Oncology

Daniel A. Vorobiof, MD, chief medical director of Belong.Life, discusses financial toxicity in oncology.

Financial toxicity is an ongoing problem in the oncology space that has not been properly addressed to date, Vorobiof says.

In the United States, cancer is among the most expensive diseases to treat, along with heart disease, Vorobiof says. Moreover, financial toxicity is a global problem and cancer-related treatment expenses are continuing to rise.

Although financial toxicity may affect all patients differently, some health care professionals have been detached from the widespread burden financial toxicity can place on a patient with cancer, concludes Vorobiof. 

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.










Daniel A. Vorobiof, MD

Articles

Dr. Vorobiof on the Impact of Financial Toxicity in the Field of Oncology

Dr. Vorobiof on Financial Toxicity in Oncology